2025 ASCO GI

CE / CME

CCO Independent Conference Highlights of the 2025 ASCO Gastrointestinal Cancers Symposium

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.50 Nursing contact hours

Pharmacists: 1.50 contact hours (0.15 CEUs)

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: April 09, 2025

Expiration: October 08, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this text-based module, Arvind Dasari, MD, MS; Christopher Lieu, MD, FASCO; and Rachna Shroff, MD, MS, FASCO, summarize and review the clinical implications of key studies on gastrointestinal (GI) cancers presented at the 2025 American Society of Clinical Oncology (ASCO) GI Cancers Symposium. 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with GI cancers do you provide care for in a typical month?

Based on data from the BREAKWATER study and subsequent accelerated FDA approval, which of the following patients could be considered for treatment with encorafenib plus cetuximab (EC) plus FOLFOX6?

Which of the following findings was reported with nivolumab plus ipilimumab vs nivolumab monotherapy in the phase III CheckMate 8HW trial in patients with advanced microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) colorectal cancer (CRC), as presented at ASCO GI 2025?

Which of the following agents is approved by the FDA for patients with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic neuroendocrine tumors (epNET)?